Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?

Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?

Introduction: The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated. We aimed to assess the effect of HIPEC after primary debulking surgery (PDS) in AOC according to patient'...

Full description

Bibliographic Details
Main Authors: Valentina Ghirardi, Francesca De Felice, Marco D'Indinosante, Federica Bernardini, Maria Teresa Giudice, Anna Fagotti, Giovanni Scambia
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Cancer Treatment and Research Communications
Subjects:
HIPEC
Ovarian cancer
Primary debulking surgery
BRCA mutation
Survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294222000107

Internet

http://www.sciencedirect.com/science/article/pii/S2468294222000107

Similar Items